Clinical trial NCT04627194: Characteristics of COVID-19 Patients in Kazakhstan in Early 2020
Official title: Epidemiological and Clinical Characteristics of COVID-19 Patients in Kazakhstan in Early 2020: a Retrospective, Observational Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Covid19
Pneumonia, Viral
Lead sponsor: Semey State Medical University
Sponsor class: OTHER
First posted: 2020-11-13
Enrollment: 1000
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Medical records will be obtained for all subjects, who presented with COVID-19-like symptoms or had a suspected exposure to SARS-CoV-2 between Feb 20 and April 30, 2020 as reported to the Republican Centre for Health Development by regional hospitals. Only those patients who had a positive SARS-CoV-2 PCR test result will be included in the analysis of primary and secondary outcome measures.

Brief summary: The aim of this study is to assess the epidemiological and clinical features of patients diagnosed with COVID-19 in Kazakhstan at the onset of the pandemic.

Detailed description: There is a paucity of data available on the epidemiological and clinical characteristics of coronavirus disease 2019 (COVID-19) in Kazakhstan. While a global effort in search for effective treatments and vaccines against COVID-19 is in effect, it is important that high quality and up-to-date information be available from a broad variety of populations on the dynamics of infection. This is especially important in regions where, due to resource shortage, epidemiologic surveillance may have gaps. To address the current gaps, medical records will be obtained for patients with confirmed COVID-19 during the first months of the pandemic (February-April 2020). The epidemiologic and clinical features including the demographics, clinical manifestation, laboratory parameters, radiologic assessments and clinical outcomes will be analyzed. The results of this study will facilitate the clinical management of COVID-19 patients in Kazakhstan and ultimately inform the ongoing efforts to curb the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the region.

Eligibility criteria: Inclusion Criteria:

* Laboratory confirmation of SARS-CoV-2 infection by polymerase chain reaction.

Primary outcomes:
measure: Clinical and demographic predictors of disease severity among hospitalized COVID-19 patients.
timeFrame: approximately 70 days
measure: Clinical and demographic predictors of mortality among hospitalized COVID-19 patients.
timeFrame: approximately 70 days
Secondary outcomes:
Other outcomes:
Locations:
city: Semey
country: Kazakhstan
facility: Semey Medical University
state: East Kazakhstan
Study officials:
affiliation: Semey State Medical University
name: Yersin Zhunussov, MD, D.M.S.
role: STUDY_CHAIR
affiliation: Semey State Medical University
name: Raifa Ivanova, MD, D.M.S.
role: STUDY_DIRECTOR
affiliation: Semey State Medical University
name: Maiya Goremykina, M.D, C.M.S
role: PRINCIPAL_INVESTIGATOR
affiliation: Nazarbayev University, School of Sciences and Humanities
name: Sergey Yegorov, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: